Clinical applications of natural killer T cell–based immunotherapy for cancer
- 21 February 2008
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 99 (4), 638-645
- https://doi.org/10.1111/j.1349-7006.2008.00730.x
Abstract
Human invariant V alpha 24 natural killer T (NKT) cells are a novel, distinct lymphocyte population, characterized by an invariant T-cell receptor V alpha 24 chain paired with V beta 11. V alpha 24 NKT cells are activated by a specific glicolipid ligand, alpha-GalCer, and rapidly produce a large amount of Th1 and Th2 cytokines, thereby modulating other immune cells such as antigen-specific CD4 and CD8 T cells, NK cells, and dendritic cells. Recent studies have shown that NKT cells play pivotal regulatory roles in many immune responses, including antitumor immunity. We herein review the quantitative alteration and functional deterioration of circulating V alpha 24 NKT cells in various cancer-bearing patients. We also summarize the recent progress in the clinical studies of NKT cell-based tumor immunotherapy. Novel immunological results including the increased peripheral blood V alpha 24 NKT cells and IFN-producing cells after the immunotherapy were revealed. The details of the safety profile and the antitumor responses were also disclosed. Although the objective clinical responses still remain unclear, some encouraging results have emerged. Therefore, NKT cell-based immunotherapy may potentially be an effective strategy for the treatment of cancer patients.Keywords
This publication has 48 references indexed in Scilit:
- Combination antibody‐based cancer immunotherapyCancer Science, 2007
- A Phase I Study ofIn vitroExpanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal CarcinomasClinical Cancer Research, 2005
- Dendritic cell maturation by CD11c− T cells and Vα24+ natural killer T‐cell activation by α‐GalactosylceramideInternational Journal of Cancer, 2005
- Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patientsThe Journal of Experimental Medicine, 2005
- Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor loadInternational Journal of Cancer, 2005
- Distinct Functional Lineages of Human Vα24 Natural Killer T CellsThe Journal of Experimental Medicine, 2002
- Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer StainingThe Journal of Experimental Medicine, 2002
- TRAIL expression by activated human CD4+Valpha24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cellsBlood, 2001
- THE CD1 SYSTEM: Antigen-Presenting Molecules for T Cell Recognition of Lipids and GlycolipidsAnnual Review of Immunology, 1999